Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 TAS-120 in metastatic breast cancer with FGFR amplification
2019-001164-30Phase 2Unknown
- Sponsor
- Taiho Oncology
- Start
- Aug 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of futibatinib in breast cancer (2 arms), sponsored by Taiho Oncology. Primary endpoint: Objective response rate. Status: unknown.
02
Drugs
futibatinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2019-001164-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001164-30.